BB Good human data, but mixed outcomes or surrogate markers. How we grade →RCT (double-blind, placebo-controlled) · 1,108 adults in China
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study
YX Chen, QY Gao, TH Zou, et al. The Lancet Gastroenterology & Hepatology. 2020.
- In plain language
- 300 mg twice a day for up to 2 years: constipation in 1% vs under 0.5% on placebo, no serious adverse events; fewer recurrent polyps.
- Limits
- Polyp outcome, not metabolic health; one country; government-funded.
- Which of our grades it feeds
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Berberine dose, side effects and drug interactions: what the trials used and who should skip it
- CC Small or few human trials. Promising, not proven. How we grade →Ratings card: Berberine HCl: Healthy glucose metabolism
- Source
- doi.org/10.1016/S2468-1253(19)30409-1 · PubMed 31926918
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.